109 related articles for article (PubMed ID: 11317082)
1. Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy.
Dorrucci M; Suligoi B; Serraino D; Tirelli U; Rezza G;
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):377-80. PubMed ID: 11317082
[TBL] [Abstract][Full Text] [Related]
2. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
Ahdieh-Grant L; Li R; Levine AM; Massad LS; Strickler HD; Minkoff H; Moxley M; Palefsky J; Sacks H; Burk RD; Gange SJ
J Natl Cancer Inst; 2004 Jul; 96(14):1070-6. PubMed ID: 15265968
[TBL] [Abstract][Full Text] [Related]
4. Risk of invasive cervical cancer among women with, or at risk for, HIV infection.
Serraino D; Carrieri P; Pradier C; Bidoli E; Dorrucci M; Ghetti E; Schiesari A; Zucconi R; Pezzotti P; Dellamonica P; Franceschi S; Rezza G
Int J Cancer; 1999 Jul; 82(3):334-7. PubMed ID: 10399949
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiretroviral therapy on the incidence of cervical neoplasia among HIV-infected women: a population-based cohort study in Taiwan.
Chen YC; Li CY; Liu HY; Lee NY; Ko WC; Ko NY
AIDS; 2014 Mar; 28(5):709-15. PubMed ID: 24326354
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program.
Massad LS; Seaberg EC; Watts DH; Hessol NA; Melnick S; Bitterman P; Anastos K; Silver S; Levine AM; Minkoff H
AIDS; 2004 Jan; 18(1):109-13. PubMed ID: 15090836
[TBL] [Abstract][Full Text] [Related]
7. Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women.
Heard I; Potard V; Costagliola D
Antivir Ther; 2006; 11(8):1091-6. PubMed ID: 17302379
[TBL] [Abstract][Full Text] [Related]
8. Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.
Grabar S; Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; Pradier C; Salmon D; Simon A; Pourcher V; Spano JP; Poizot-Martin I; Costagliola D
HIV Med; 2019 Mar; 20(3):222-229. PubMed ID: 30693646
[TBL] [Abstract][Full Text] [Related]
9. AIDS malignancies in the era of highly active antiretroviral therapy.
Gates AE; Kaplan LD
Oncology (Williston Park); 2002 May; 16(5):657-65; discussion 665, 668-70. PubMed ID: 12108891
[TBL] [Abstract][Full Text] [Related]
10. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.
Cobucci RN; Lima PH; de Souza PC; Costa VV; Cornetta Mda C; Fernandes JV; Gonçalves AK
J Infect Public Health; 2015; 8(1):1-10. PubMed ID: 25294086
[TBL] [Abstract][Full Text] [Related]
11. Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.
Abraham AG; D'Souza G; Jing Y; Gange SJ; Sterling TR; Silverberg MJ; Saag MS; Rourke SB; Rachlis A; Napravnik S; Moore RD; Klein MB; Kitahata MM; Kirk GD; Hogg RS; Hessol NA; Goedert JJ; Gill MJ; Gebo KA; Eron JJ; Engels EA; Dubrow R; Crane HM; Brooks JT; Bosch RJ; Strickler HD;
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):405-13. PubMed ID: 23254153
[TBL] [Abstract][Full Text] [Related]
12. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women.
Charurat M; Blattner W; Hershow R; Buck A; Zorrilla CD; Watts DH; Paul M; Landesman S; Adeniyi-Jones S; Tuomala R;
J Womens Health (Larchmt); 2004; 13(6):719-30. PubMed ID: 15333287
[TBL] [Abstract][Full Text] [Related]
13. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
[TBL] [Abstract][Full Text] [Related]
14. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
Boulassel MR; Morales R; Murphy T; Lalonde RG; Klein MB
J Med Virol; 2006 Sep; 78(9):1158-63. PubMed ID: 16847953
[TBL] [Abstract][Full Text] [Related]
15. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
Gingues S; Gill MJ
HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
[TBL] [Abstract][Full Text] [Related]
17. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.
de Martino M; Tovo PA; Balducci M; Galli L; Gabiano C; Rezza G; Pezzotti P
JAMA; 2000 Jul; 284(2):190-7. PubMed ID: 10889592
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.
Pérez-Hoyos S; del Amo J; Muga R; del Romero J; García de Olalla P; Guerrero R; Hernàndez-Aguado I;
AIDS; 2003 Feb; 17(3):353-9. PubMed ID: 12556689
[TBL] [Abstract][Full Text] [Related]
19. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
[TBL] [Abstract][Full Text] [Related]
20. The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort.
Altmann M; An der Heiden M; Scheufele R; Hartmann K; Houareau C; Bartmeyer B; Hamouda O;
BMC Infect Dis; 2012 Apr; 12():94. PubMed ID: 22515400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
